Sign in
Taking people in South KoreaNo phase

Personalized Magnetic Brain Stimulation to Improve Arm Use After Stroke

Tests tailored magnetic brain stimulation to aid arm recovery in people with recent stroke.

Key facts

Who runs it
Samsung Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients
Status
Recruiting
People taking part
120 people, planned
Started
13 Feb 2024
Planned end
30 Sept 2026
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High-Frequency1
  • cTBS1
  • High-Frequency2
  • cTBS2
  • High-Frequency3
  • cTBS3
Record updated
24 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital who had a stroke 7 days to 3 months ago, with weakness on one side and reduced arm function.

Age
19 years and older
Sex
All sexes can join.
Disease stage
Stroke with weakness on one side (hemiplegia), in the subacute phase: 7 days to 3 months after onset. Upper arm and hand score (FMA) of 42 or less.

Main reasons for not taking part

  • Epilepsy, metal implants in the head, or past brain surgery (craniotomy)
  • Other nerve diseases such as spinal cord injury or Parkinson's disease
  • Major mental illness such as major depression, schizophrenia or dementia
  • Unstable or worsening medical condition
  • Cannot have an MRI scan, or is pregnant or breastfeeding

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • hemiplegic stroke patients in the subacute phase (7 days to 3 months from the onset) who are currently hospitalized,
  • FMA score of the upper extremity ≤42,
  • adequate language and cognitive function to perform at least a 1-step obey-command,
  • pre-stroke functional level of modified Rankin Scale (mRS) ≤1,
  • aged ≥19 years old,
  • patients willing to sign the informed consent

Who cannot take part

  • those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,
  • those with progressive of hemodynamically unstable medical conditions,
  • those with coexisting neurological conditions, such as spinal cord injury or Parkinson's disease,
  • those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,
  • those having contraindications to conduct an MRI study,
  • those who are pregnant or lactating ,
  • patients who have refused to participate in this study

Where in South Korea

  • Samsung Medical CenterSeoul, South KoreaContact: Won Hyuk Chang, PhDTaking people

About the trial

What the trial wants to find out

The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each hemiplegic stroke patient in subacute phase, compared to conventional low-frequency rTMS therapy on contralateral M1. Investigators hypothesized that the functional reserve of each hemiplegic stroke patient will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to stroke patients regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.

The 6 groups in the trial

  • High-Frequency1Treatment being tested

    Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract. High-frequency rTMS over ipsilateral primary motor cortex will be applied.

  • cTBS1Existing treatment, for comparison

    Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract. continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied.

  • High-Frequency2Treatment being tested

    Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract. High-frequency rTMS over ipsilateral premotor cortex will be applied.

  • cTBS2Existing treatment, for comparison

    Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract. continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied.

  • High-Frequency3Treatment being tested

    Absent responses in all ipsilateral corticospinal tract. High-frequency rTMS over contralateral primary motor cortex will be applied.

  • cTBS3Existing treatment, for comparison

    Absent responses in all ipsilateral corticospinal tract. continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients: A Multi Center, Randomized, Single Blind, Parallel Group Prospective Clinical Trial
Plain-language title
Personalized Magnetic Brain Stimulation to Improve Arm Use After StrokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
24 April 2026